Related Experiment Video
Updated: May 20, 2026
08:18
A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)
Published on: December 26, 2015
Current and emerging therapies in multiple sclerosis: a systematic review.
Wanda Castro-Borrero1, Donna Graves, Teresa C Frohman
1University of Connecticut Health Center, Neurology Associates, 263 Farmington Ave., Farmington, CT 06030-5357, USA.
Therapeutic Advances in Neurological Disorders
|July 12, 2012
Summary
Multiple sclerosis (MS) is a chronic autoimmune neurological disease affecting young adults. While new therapies manage relapsing forms, a cure halting neurodegeneration remains elusive.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Multiple sclerosis (MS) is a chronic, disabling autoimmune neurological disease primarily impacting young adults.
- Significant advancements in understanding MS pathophysiology have occurred over the last 25 years.
- Current disease-modifying therapies (DMTs) effectively manage relapsing-remitting MS (RRMS) by preventing exacerbations and new lesions.
Purpose of the Study:
- To review approved and emerging therapies for multiple sclerosis.
- To detail the mechanism of action, indications, side effects, and safety of MS treatments.
- To discuss potential off-label drug uses for managing MS.
Main Methods:
- Literature review of Food and Drug Administration (FDA) and European Medicines Agency (EMA) approved agents.
- Analysis of emerging therapies and drugs for off-label MS use.
- Synthesis of information on drug mechanisms, efficacy, and safety profiles.
Main Results:
- Multiple disease-modifying therapies (DMTs) are available for relapsing-remitting MS (RRMS).
- These therapies focus on managing disease activity and preventing new lesions.
- No current treatment completely halts the underlying neurodegenerative process in MS.
Conclusions:
- The review provides a comprehensive overview of current and emerging MS treatments.
- It highlights the limitations of existing therapies in halting neurodegeneration.
- It serves as a guide for clinicians regarding approved, emerging, and off-label therapeutic options for MS management.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...